Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Vaxart total assets
Total assets on the balance sheet at the end of each period.
Vaxart's total assets was $148.18M at Sep 30, 2026. For fiscal 2025 it was $186.08M, up 11.8% from the year before. Over ten years it grew 5.0% a year on average. The highest annual figure on record is $221.17M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.08M | +11.8% |
| FY2024 | Dec 31, 2024 | $166.39M | +81.2% |
| FY2023 | Dec 31, 2023 | $91.83M | -40.3% |
| FY2022 | Dec 31, 2022 | $153.85M | -30.4% |
| FY2021 | Dec 31, 2021 | $221.17M | +45.0% |
| FY2020 | Dec 31, 2020 | $152.58M | +312.0% |
| FY2019 | Dec 31, 2019 | $37.03M | +5.1% |
| FY2018 | Dec 31, 2018 | $35.23M | -51.5% |
| FY2016 | Jun 30, 2016 | $72.70M | -8.4% |
| FY2015 | Jun 30, 2015 | $79.40M | -30.4% |
| FY2014 | Jun 30, 2014 | $114.00M | +32.9% |
| FY2013 | Jun 30, 2013 | $85.80M | +23.8% |
| FY2012 | Jun 30, 2012 | $69.30M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $148.18M | -29.1% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $165.19M | +0.7% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $180.06M | +13.6% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $186.08M | +11.8% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $208.99M | +25.4% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $164.09M | +44.3% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $158.56M | +78.8% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $166.39M | +81.2% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $166.67M | +57.8% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $113.75M | -7.3% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $88.67M | -31.7% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $91.83M | -40.3% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $105.64M | -39.7% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $122.65M | -32.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $129.85M | -35.2% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $153.85M | -30.4% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $175.31M | -27.3% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $181.45M | -20.7% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $200.38M | -2.7% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $221.17M | +45.0% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $241.14M | +55.9% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $228.84M | +256.5% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $205.87M | +291.6% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $152.58M | +312.0% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $154.71M | +262.4% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $64.19M | +72.3% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $52.56M | +44.8% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $37.03M | +5.1% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $42.70M | +5.1% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $37.25M | -22.0% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $36.31M | -35.8% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $35.23M | -51.5% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $40.64M | -34.4% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $47.76M | -25.6% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $56.54M | -20.4% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $72.70M | -8.4% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $61.90M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $64.20M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $71.00M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $79.40M | – |
See a number that looks wrong?